A Study of Ruxolitinib in Pancreatic Cancer Patients
Public ClinicalTrials.gov record NCT02119663. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-Blind, Phase 3 Study of the JAK 1/2 Inhibitor Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy (The JANUS 2 Study)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This was to determine the efficacy, based upon overall survival, of ruxolitinib added to capecitabine for the treatment of metastatic pancreatic cancer.
Study identification
- NCT ID
- NCT02119663
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 86 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 31, 2014
- Primary completion
- Jan 31, 2016
- Completion
- Sep 30, 2016
- Last update posted
- Feb 12, 2018
2014 – 2016
United States locations
- U.S. sites
- 55
- U.S. states
- 28
- U.S. cities
- 55
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Huntsville | Alabama | — | — |
| Not listed | Fayetteville | Arkansas | — | — |
| Not listed | Beverly Hills | California | — | — |
| Not listed | La Jolla | California | — | — |
| Not listed | Aurora | Colorado | — | — |
| Not listed | Denver | Colorado | — | — |
| Not listed | Washington D.C. | District of Columbia | — | — |
| Not listed | Fort Myers | Florida | — | — |
| Not listed | St. Petersburg | Florida | — | — |
| Not listed | Athens | Georgia | — | — |
| Not listed | Atlanta | Georgia | — | — |
| Not listed | Macon | Georgia | — | — |
| Not listed | Thomasville | Georgia | — | — |
| Not listed | Harvey | Illinois | — | — |
| Not listed | Indianapolis | Indiana | — | — |
| Not listed | Kansas City | Kansas | — | — |
| Not listed | Louisville | Kentucky | — | — |
| Not listed | Baltimore | Maryland | — | — |
| Not listed | Boston | Massachusetts | — | — |
| Not listed | Farmington Hills | Michigan | — | — |
| Not listed | Kalamazoo | Michigan | — | — |
| Not listed | Lansing | Michigan | — | — |
| Not listed | Minneapolis | Minnesota | — | — |
| Not listed | Saint Louis Park | Minnesota | — | — |
| Not listed | Bolivar | Missouri | — | — |
| Not listed | Basking Ridge | New Jersey | — | — |
| Not listed | Cherry Hill | New Jersey | — | — |
| Not listed | Voorhees Township | New Jersey | — | — |
| Not listed | Commack | New York | — | — |
| Not listed | Fresh Meadows | New York | — | — |
| Not listed | Harrison | New York | — | — |
| Not listed | New York | New York | — | — |
| Not listed | Rochester | New York | — | — |
| Not listed | Rockville Centre | New York | — | — |
| Not listed | Sleepy Hollow | New York | — | — |
| Not listed | Canton | Ohio | — | — |
| Not listed | Cincinnati | Ohio | — | — |
| Not listed | Portland | Oregon | — | — |
| Not listed | Allentown | Pennsylvania | — | — |
| Not listed | Hershey | Pennsylvania | — | — |
| Not listed | Langhorne | Pennsylvania | — | — |
| Not listed | Greenville | South Carolina | — | — |
| Not listed | Chattanooga | Tennessee | — | — |
| Not listed | Knoxville | Tennessee | — | — |
| Not listed | Nashville | Tennessee | — | — |
| Not listed | Dallas | Texas | — | — |
| Not listed | Fort Worth | Texas | — | — |
| Not listed | Lubbock | Texas | — | — |
| Not listed | San Antonio | Texas | — | — |
| Not listed | Temple | Texas | — | — |
| Not listed | Salt Lake City | Utah | — | — |
| Not listed | Falls Church | Virginia | — | — |
| Not listed | Newport News | Virginia | — | — |
| Not listed | Seattle | Washington | — | — |
| Not listed | Green Bay | Wisconsin | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 40 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02119663, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 12, 2018 · Synced Sep 4, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02119663 live on ClinicalTrials.gov.